← Back to Clinical Trials
Recruiting NCT06696625

NCT06696625 Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06696625
Status Recruiting
Phase
Sponsor Beijing Tongren Hospital
Condition Dry Eye Disease
Study Type INTERVENTIONAL
Enrollment 256 participants
Start Date 2021-07-01
Primary Completion 2025-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation0.1% sodium hyaluronate eye drop

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 256 participants in total. It began in 2021-07-01 with a primary completion date of 2025-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease. Methods: The investigators enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months. OSDI score, TBUT, Schirmer I, CFS, SF36, DEQ5, and psychological status to evaluate the therapeutic effects. A difference of P \< 0.05 was considered statistically significant.

Eligibility Criteria

Inclusion Criteria: 1. Age \>=18 and Age \<=65. 2. complaint of DED symptoms for 6 months or longer at screening. 3. ocular surface disease index (OSDI) score of 25 or higher. 4. tear film breakup time (TFBUT) of 5 seconds or less. 5. Schirmer I test without anesthesia of 5 mm or more at 5 minutes. 6. tCFS score of 4 or higher. Exclusion Criteria: 1. History systemic autoimmune diseases and ocular/periocular malignancy. 2. Clinically relevant slitlamp findings or abnormal lid anatomy. 3. Active ocular allergies and active infection. 4. Pregnant or lactating women.

Contact & Investigator

Central Contact

Dong Wu, Doctor

✉ wudong0120@outlook.com

📞 8613810988682

Frequently Asked Questions

Who can join the NCT06696625 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Dry Eye Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06696625 currently recruiting?

Yes, NCT06696625 is actively recruiting participants. Contact the research team at wudong0120@outlook.com for enrollment information.

Where is the NCT06696625 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06696625 clinical trial?

NCT06696625 is sponsored by Beijing Tongren Hospital. The trial plans to enroll 256 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology